Nanoparticle medicine company Nanoform said that proof of concept studies may now be performed for Boehringer Ingelheim to assess the added value Nanoform’s CESS technology can deliver to its drug development projects.
 
The two parties executed a master services agreement (MSA) to initiate projects in the pre-clinical early development space with the aim of solving the ever-growing challenge of poor bioavailability and solubility in new drug candidates—a leading cause of drug development failure.
 
“Wider uptake of the latest technological innovations is essential to address the low success rates for new drug candidates in pharma,” said Christian Jones, chief commercial officer, Nanoform. “We are delighted to collaborate with Boehringer Ingelheim to evaluate how our proprietary CESS platform can help more novel therapies reach the patients who need them. This is the first step toward what we hope will be a long and fruitful partnership between our companies.”